Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jon Benson

Physician Assistant Marion, OH Physician Assistant

NPI 1922030956 CMS profile 588527

1063 Harding Memorial Pkwy, Marion, OH 43302

Open in the dashboard

General payments

$19,101

966 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Benson of Marion, OH is reported in the CMS Open Payments database as having received $19,101 across 966 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,695 244
2024 General $3,739 215
2023 General $4,303 191
2022 General $3,609 170
2021 General $2,754 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Benson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jon Benson were reported at $4,695. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jon Benson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,754 $132 $37–$438 $132
2022 $3,609 $155 $48–$522 $149
2023 $4,303 $167 $52–$557 $160
2024 $3,739 $178 $55–$600 $164
2025 $4,695 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $2,941 44 payments
  2. AbbVie, Inc. $2,216 179 payments
  3. Sun Pharmaceutical Industries Inc. $1,757 78 payments
  4. UCB, Inc. $1,453 72 payments
  5. Janssen Biotech, Inc. $1,381 81 payments
  6. Genzyme Corporation $1,276 61 payments
  7. E.R. Squibb & Sons, L.L.C. $1,161 57 payments
  8. Lilly USA, LLC $1,057 50 payments
  9. LEO Pharma Inc. $941 57 payments
  10. Incyte Corporation $939 55 payments
  11. Other $3,978 232 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,036 952 payments
  2. Consulting Fee $1,166 2 payments
  3. Education $899 12 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $2,387 31 payments
  2. DUPIXENT Immunology $1,354 76 payments
  3. TREMFYA $1,307 66 payments
  4. RINVOQ $1,163 80 payments
  5. SOTYKTU $1,156 55 payments
  6. OPZELURA $939 55 payments
  7. TALTZ $896 45 payments
  8. ADBRY $781 45 payments
  9. ILUMYA $755 38 payments
  10. Bimzelx $744 37 payments
  11. Other $7,531 514 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,413

Median for Physician Assistant: 241

Drug cost

$2,913,163

Median for Physician Assistant: $4,110

Branded share of claims

22.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 256 $992,984
Humira(Cf) Pen Adalimumab Brand 39 $458,129
Tremfya Guselkumab Brand 27 $366,111
Taltz Autoinjector Ixekizumab Brand 36 $247,896
Cosentyx Sensoready (2 Pens) Secukinumab Brand 29 $213,474
Rinvoq Upadacitinib Brand 20 $165,530
Cosentyx (2 Syringes) Secukinumab Brand 12 $109,353
Humira(Cf) Adalimumab Brand 14 $94,213
Cosentyx Unoready Pen Secukinumab Brand 11 $88,078
Otezla Apremilast Brand 15 $64,466

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$166,273

Of which drugs: $40

Medicare patients

728

Average age 74

Services billed

3,048

370 women, 358 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 33%
Ischemic heart disease 26%
Chronic kidney disease 22%
Atrial fibrillation 21%
Depression 19%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 61 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$393 256 —
RINVOQ
$359 20 —
TREMFYA
$331 27 —
SOTYKTU
$330 — —
ADBRY
$306 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

966 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record